ArticleEClinicalMedicine2023

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study.

Marek Trněný et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.